The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Khitrova A.N.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

Bolotina L.V.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdravsotsrazvitiia Rossii

Kornietskaia A.L.

FGBU "Moskovskiĭ nauchno-issledovatel'skiĭ onkologicheskiĭ institut im. P.A. Gertsena" Minzdrava Rossii

Moskvicheva L.I.

P.A. Herzen Moscow Oncology Research Institute, Branch, National Medical Radiology Research Center, Ministry of Health of Russia, Moscow, Russia

High-intensity focused ultrasound therapy as part of combined treatment for inoperable pancreatic cancer

Authors:

Khitrova A.N., Bolotina L.V., Kornietskaia A.L., Moskvicheva L.I.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2020;9(1): 50‑54

Read: 3076 times


To cite this article:

Khitrova AN, Bolotina LV, Kornietskaia AL, Moskvicheva LI. High-intensity focused ultrasound therapy as part of combined treatment for inoperable pancreatic cancer. P.A. Herzen Journal of Oncology. 2020;9(1):50‑54. (In Russ.)
https://doi.org/10.17116/onkolog2020901150

Recommended articles:
Small cell carcinoma of the paro­tid gland. P.A. Herzen Journal of Onco­logy. 2025;(4):69-74
Prevention and basic therapy of skin toxic reactions in children receiving anti-cancer drug therapy. Part 1. Russian Journal of Clinical Dermatology and Vene­reology. 2025;(6):828-836

References:

  1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(1):69-90. https://doi.org/10.3322/caac.20107
  2. Raimondi S, Maisonneuve P, Lowenfels AB. Epidemiology of pancreatic cancer: an overview. Nat Rev Gastroenterol Hepatol. 2009;6(12):699-708. https://doi.org/10.1038/nrgastro.2009.177
  3. Yamagishi Y, Higuchi H, Izumiya M, Sakai G, Iizuka H, Nakamura S, Adachi M, Hozawa S, Takaishi H, Hibi T. Gemcitbine as first-line chemotherapy in elderly patients with unresectable pancreatic carcinoma. J Gastroenterol. 2010;45(11):1146-1154. https://doi.org/10.1007/s00535-010-0258-9
  4. Hanada K, Hino F, Amano H, Fukuda T, Kuroda Y. Current treatment strategies for pancreatic cancer in the elderly. Drugs Aging. 2006;23(5):403-410. https://doi.org/10.2165/00002512-200623050-00004
  5. Marechal R., Demols A, Gay F, de Maertelaer V, Arvanitaki M, Hendlisz A, Van Laethem JL. Tolerance and efficacy of gemcitabine and gemcitabine-baced regimens in elderly patients with advanced pancreatic cancer. Pancreas. 2008;36(3):16-21. https://doi.org/10.1097/mpa.0b013e31815f3920
  6. Hentic O, Dreyer C, Rebours V, Zappa M, Lévy P, Raymond E, Ruszniewski P, Hammel P. Gemcitabine in elderly patients with advanced pancreatic cancer. World J Gastroenterol. 2011;17(30):3497-3502. https://doi.org/10.3748/wjg.v17.i30.3497
  7. Kuroda T, Kumagi T, Yokota T, Azemoto N, Hasebe A, Seike H, Nishiyama M, Inada N, Shibata N, et al. Efficacy of chemotherapy in elderly patients with unresectable pancreatic cancer: a multicenter review of 895 patients. BMC Gastroenterology. 2017;17(1):66. https://doi.org/10.1186/s12876-017-0623-8
  8. Bjerregaard JK, Mortensen MB, Schønnemann KR, Pfeiffer P. Characteristics, therapy and outcome in an unselected and prospectively registered cohort of pancreatic cancer patients. Eur J Cancer. 2013;49(1):98-105. https://doi.org/10.1016/j.ejca.2012.07.017
  9. Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25(15):1960-1966. https://doi.org/10.1200/JCO.2006.07.9525
  10. Trouilloud I, Dupont-Gossard AC, Malka D, Artru P, Gauthier M, Lecomte T, Aparicio T, Thirot-Bidault A, Lobry C, Asnacios A, et al. Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM). Eur J Cancer. 2014;50(18):3116-3124. https://doi.org/10.1016/j.ejca.2014.09.015
  11. Caparello C, Meijer LL, Garajova I, Falcone A, Le Large TY, Funel N, Kazemier G, Peters GJ, Vasile E, Giovannetti E. FOLFIRINOX and translational studies: Towards personalized therapy in pancreatic cancer. World J Gastroenterol. 2016;22(31):6987-7005. https://doi.org/10.3748/wjg.v22.i31.6987
  12. Keane MG, Bramis K, Pereira SP, Fusai GK. Systematic review of novel ablative methods in locally advanced pancreatic cancer. World J Gastroenterol. 2014;20(9):2267-2278. https://doi.org/10.3748/wjg.v20.i9.2267
  13. Gao HF, Wang K, Meng ZQ, Chen Z, Lin JH, Zhou ZH, Wang P, Shi WD, Sheng YH. High intensity focused ultrasound treatment for patients with local advanced pancreatic cancer. Hepatogastroenterology. 2013;60(128):1906-1910. https://doi.org/10.1155/2014/205325
  14. Zhang L, Wang ZB. High-intensity focused ultrasound tumor ablation: review of ten years of clinical experience. Front Med China. 2010;4:294-302. https://doi.org/10.1007/s11684-010-0092-8
  15. Sofuni A, Moriyasu F, Sano T, Yamada K, Itokawa F, Tsuchiya T, Tsuji S, Kurihara T, Ishii K, Itoi T. The current potential of high-intensity focused ultrasound for pancreatic carcinoma. J Hepatobiliary Pancreat Sci. 2011;18(3):295-303. https://doi.org/10.1007/s00534-010-0355-4
  16. Seufferlein T, Porzner M, Heinemann V, Tannapfel A, Stuschke M, Uhl W. Ductal pancreatic adenocarcinoma. Deutsch Arztebl Int. 2014;111(22):396-402. https://doi.org/10.3238/arztebl.2014.0396
  17. Suleimanov EA, Filonenko EV, Moskvicheva LI, Kaprin AD, Kostin AA, Samsonov YuV, Isaev AR. The possibility of HIFU therapy at the present stage. Issledovaniya i praktika v meditsine (Research and Practical Medicine Journal). 2016;3(3):76-82. (In Russ.) https://doi.org/10.17709/2409-2231-2016-3-3-8
  18. Marinova M, Huxold HC, Henseler J, Mücke M, Conrad R, Rolke R, Ahmadzadehfar H, Rauch M, Fimmers R, Luechters G, et al. Clinical effectiveness and potential survival benefit of US-guided high-intensity focused ultrasound therapy in patients with advanced-stage pancreatic cancer. Ultraschall Med. 2019;40(5):625-637. https://doi.org/10.1055/a-0591-3386
  19. Zhou D, Lv W, Yan T, Wang G, Zhao W, Zhang T. High-intensity focused ultrasound therapy in combination with gemcitabine for unresectable pancreatic carcinoma. Ther Clin Risk Manag. 2016;12:687-691. https://doi.org/10.2147/tcrm.s90567
  20. Moskvicheva LI, Petrov LO, Sidorov DV. The possibilities of modern methods of ablation in non-resectable locally advanced pancreatic cancer. Issledovaniya i praktika v meditsine (Research and Practical Medicine Journal). 2018;5(2):86-99. (In Russ.) https://doi.org/10.17709/2409-2231-2018-5-2-10

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.